Aura Biosciences Q4 EPS $(0.37) Beats $(0.45) Estimate

Aura Biosciences (NASDAQ: AURA) reported a Q4 EPS loss of $(0.37), which exceeded the analyst consensus estimate of $(0.45) by 17.78%. This represents a 28.85% improvement compared to the $(0.52) per share loss reported in the same quarter last year.